3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients

3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients
An ongoing observational registry study is evaluating Kiyatec's novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D) assay as a predictor of chemotherapy responses in ovarian cancer patients whose disease is newly diagnosed or recurred after prior treatment. The Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) is the most recent institution joining this observational study, the company announced in a press release. Enrollment is ongoing; more information on contacts and locations is available here. “Ovarian cancer patients and clinicians do not have the luxury of time to experiment with drug therapies they don’t know will work, so we developed our investigational ovarian cancer drug response profile to help optimize therapeutic decision-making over the course of the disease,” said Matthew Gevaert, CEO of Kiyatec. “We are delighted to welcome UAMS to the 3D-PREDICT study as we endeavor to deliver on the promise of pre-treatment, patient-specific drug response profiling for ovarian cancer,” Gevaert added. 3D-PREDICT is expected to recruit about 570 participants at several sites in the U.S. In the study, patient tumor samples collected during biopsies or cancer removal surgery will be exposed to a panel of 11 different medicines commonly used to treat people with newly diagnosed or recurrent ovarian cancer. The study builds up on data from an earlier pilot study that provided preliminary evidence of the assay’s effectiveness at predicting the respo
Subscribe or to access all post and page content.